Thiotepa-based reduced intensity conditioning regimen: a 10 year follow up
暂无分享,去创建一个
A. Ibatici | F. Frassoni | T. Lamparelli | A. Bacigalupo | F. Gualandi | A. Dominietto | A. Raiola | D. Occhini | B. Bruno | S. Bregante | M. V. Lint | C. D. Grazia
[1] A. Gratwohl,et al. Increasing use of reduced intensity conditioning transplants: report of the 2001 EBMT activity survey , 2002, Bone Marrow Transplantation.
[2] F. Frassoni,et al. Reduced intensity thiotepa–cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age , 2000, British journal of haematology.
[3] S. Mackinnon,et al. One antigen mismatched related donor bone marrow transplant in a patient with acute lymphoblastic leukaemia and β-thalassaemia major: potential cure of both marrow disorders , 2000, Bone Marrow Transplantation.
[4] R. Storb,et al. Mixed Hematopoietic Chimerism after Marrow Allografts Transplantation in the Ambulatory Care Setting , 1999, Annals of the New York Academy of Sciences.
[5] N. Ueno,et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] A. Nagler,et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.